Journal: British Journal of Cancer

Article Title: Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

doi: 10.1038/bjc.2014.519

Figure Lengend Snippet: Comparison of mean IC 50 values between HER2-amplified and -non-amplified cell lines. ( A ) Comparison of mean IC 50 values for each HER2-amplified and -non-amplified cell line run in triplicate. ( B ) Comparison of the overall mean IC 50 values for HER2-amplified and -non-amplified cell lines each represented in triplicate.

Article Snippet: Cells were allowed to incubate with primary antibody to P-HER2/neu-1221, P-S6 (Cell Signaling Technologies, Danvers, MA, USA), or no primary antibody for 1 h on ice.

Techniques: Amplification

Journal: British Journal of Cancer

Article Title: Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

doi: 10.1038/bjc.2014.519

Figure Lengend Snippet: Comparison of mean fluorescence intensity (MFI) of ErbB1 in HER2-amplified vs -non-amplified cell lines. The figure depicts a comparison of the MFI of ErbB1 by direct staining as detected using flow cytometry between HER2-amplified and -non-amplified cell lines.

Article Snippet: Cells were allowed to incubate with primary antibody to P-HER2/neu-1221, P-S6 (Cell Signaling Technologies, Danvers, MA, USA), or no primary antibody for 1 h on ice.

Techniques: Fluorescence, Amplification, Staining, Flow Cytometry

Journal: British Journal of Cancer

Article Title: Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

doi: 10.1038/bjc.2014.519

Figure Lengend Snippet: Representative changes in S6 phosphorylation with afatinib treatment HER2-amplified vs -non-amplified cell lines. Representative changes in phosphorylation of the transcription factor S6 after treatment with scalar amounts of afatinib in ( A ) HER2-amplified (ARK2) and ( B ) -non-amplified (ARK11) cell lines 8 h after treatment.

Article Snippet: Cells were allowed to incubate with primary antibody to P-HER2/neu-1221, P-S6 (Cell Signaling Technologies, Danvers, MA, USA), or no primary antibody for 1 h on ice.

Techniques: Amplification

Journal: British Journal of Cancer

Article Title: Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

doi: 10.1038/bjc.2014.519

Figure Lengend Snippet: Comparison of mean fluorescence intensity (MFI) for phosphorylated HER2 and phosphorylated S6. Comparison of the MFI of phosphorylated HER2 ( A ) and phosphorylated S6 at 10 h ( B ) in HER2-amplified cell line ARK 2 after treatment with afatinib at a concentration of 5 n M (IC 50 ), 50 n M (human serum concentration after 24 h of 40 mg of afatinib by mouth), and 175 n M (human serum concentration after 28 days of 40 mg of afatinib by mouth daily).

Article Snippet: Cells were allowed to incubate with primary antibody to P-HER2/neu-1221, P-S6 (Cell Signaling Technologies, Danvers, MA, USA), or no primary antibody for 1 h on ice.

Techniques: Fluorescence, Amplification, Concentration Assay